4immune Therapeutics

Pipeline

Pipeline

4immune is rapidly advancing its lead program with plans to initiate our first clinical study in 2025. Our pipeline includes our lead therapeutic for early-stage type 1 diabetes, as well as ongoing discovery of treatments targeting multiple sclerosis and rheumatoid arthritis.

Targeted CAL/CAR T Cell Therapy for Type 1 Diabetes


4immune’s lead program targets patients with early-stage type 1 diabetes (T1D), a T cell-mediated autoimmune disorder in which a person’s own immune cells destroy the insulin-producing beta cells in the pancreas.  In the absence of beta cells, the body can no longer produce insulin, and can therefore no longer control blood glucose levels. 


Each year, approximately 64,000 individuals, at an average age of 13, are diagnosed with T1D in the United States. There are presently no approved curative therapies for type 1 diabetes. 



Type 1 Diabetes

How CAL/CAR T Cell Therapy Works


Prior to introducing 4immune's CAL/CAR T Cell Therapy, diabetes inducing T Cells are free to destroy healthy islet beta cells, resulting in life-long suffering from type 1 diabetes.


Killing the deleterious cells in early stages of the disease protects the healthy cells and helps to maintain homeostasis.  Early treatment can make all the difference.




How CAL/CAR T Cell Therapy Works


4immune’s CAL/CAR T cells target and selectively eliminate the autoreactive T cells implicated in the destruction of healthy cells.

Share by: